Thank you for submitting your manuscript to the EMBO Journal. Your study has now been seen by three referees and their comments are provided below.
While referee #3 is not persuaded that the advance provided over your previous work is sufficient for publication here, referees #1 and 2 are more supportive. Both referees find the analysis well done, interesting and suitable for publication here. Most of the issues raised can be fairly easily addressed. Given the opinions of referees #1 and 2, I will go with their overall recommendation and invite you to submit a suitably revised manuscript.
When preparing your letter of response to the referees' comments, please bear in mind that this will form part of the Review Process File, and will therefore be available online to the community. For more details on our Transparent Editorial Process, please visit our website: http://www.nature.com/emboj/about/process.html Thank you for the opportunity to consider your work for publication. I look forward to seeing your revision.
REFEREE REPORTS

Referee #1
The manuscript by Cancellotti et al examines the effect of normal prion protein (PrPC) glycosylation on disease phenotype during a transmissible spongiform encephalopathy (TSE or prion) infection. Three different lines of wild-type mice were inoculated with 3 different TSE strains derived from mice expressing PrPC deficient at the first (G1), second (G2), or both (G3) glycosylation sites. TSE strain phenotypes in each wild-type mouse line were evaluated using disease incubation periods, deposition patterns of infectious prion protein (PrPSc), brain lesion profiles, and the standard scrapie cell assay. They find that the phenotypic characteristics of one of the strains (79A) were altered when passaged through PrPC glycosylation deficient mice. They conclude that this occurs through a selection of mutant TSE strains.
The manuscript is well-written with clearly presented data. The results are intriguing and would be of interest to prion researchers.
As discussed by the authors, switching between the 79A and 139A phenotypes has been observed before when wild-type mice are infected with normally glycosylated PrPSc (Dickinson et al. 1984 , Carp et al. 1997 . The data in the current manuscript suggest that switching between the 79A and 139A phenotypes also happens when glycosylation deficient PrPSc is used (Pg. 20) . Given this, are the results using glycosylation deficient PrPSc really all that different from those using wild-type PrPSc? Is it possible that the lack of glycosylation is not significantly changing the way 79A normally acts in vivo? It would be helpful for the authors to more clearly explain how their data using glycosylation deficient PrPSc advances our understanding of strain switching over that of earlier studies using wild-type PrPSc.
While the discussion of the data is interesting, at times it is unclear what exactly the authors mean by some of their conclusions. At several points during the discussion they bring up the idea of mutation. In the context of an infectious agent that is primarily composed of a misfolded protein, what exactly do they mean by "mutational change" or "mutational switching"? Mechanistically, how does the loss of a single glycosylation site result in a mutant prion? What is being mutated? Is the mutation the loss of glycosylation or something else? What do they mean by "a single mutational switch" which leads to both 79A and 139A being present at high frequencies in the sample (pg. 20)? The authors need to more clearly define what they believe constitutes a mutation in a prion.
Minor comments: 1.On page 7 the text states that "The PrPSc glycotype profile of the inocula used was confirmed by Western blotting analysis (Figure 1 )". However, it is clear from the figure that not all of the inocula used are represented. It appears that the figure is intended more to show an example of the PrPSc glycotype in the PrPC glycosylation deficient mice than the actual inocula. The authors should at least note in the figure legend what PrPSc strain was used in the blot shown.
2.In the legend to Figure 2C , the authors need to indicate exactly what the very small green triangle and arrow represent.
3.The text and legend to figure 6 reference panels A and B but the panels are not labeled as such in the figure. This should be fixed.
4.In the bottom set of panels in Figure 7 , G1 needs to be changed to G2.
Referee #2
This manuscript describes effects of a lack of glycosylation at one or both of the N-linked glycosylation sites on PrP on TSE strain propagation in mice. This is an important subject and the authors provide a thorough and interesting comparison of differential glycosylation effects on several rodent-adapted TSE strains. They conclude that glycosylation can influence the stability of strains and propose that this effect is through the selection of "mutant" strains. The data and presentation are clear and significant for the most part, but I have a few relatively minor suggestions and concerns. 1) Although there is liberal use of the term "mutation" I could not find an explicit description of what the authors mean by this in the context of an agent that is largely PrPSc, without a nucleic acid genome.
2) One early (i.e. on p. 8) source of confusion in the Results section is the lack of an explanation of the mouse strain that was used to prepare the initial wt inocula for each TSE strain. I assume it is OLA 129, but am not sure. 3) P.9, nine lines from bottom: the sentence ending with "especially observed" needs fixing. 4) P.10: It seems that "over 100 days" should be "~100 days" because by my calculation, one of the differences to which the authors refer was slightly less than 100 days. 5) The authors frequently make comparisons to the 139A strain without showing data or giving references to previously published data. One or the other should be provided. 6) P13, third line from bottom: G2 is mentioned, but the figure 7E is labeled G1. I assume the former is correct? 7)The Discussion seems to be somewhat longer than it needs to be in that it contains a lot of restatements/summaries of the results.
Referee #3
This article is a follow up of previous studies from Manson's group aiming to investigate the role of PrP glycosylation on prion strain characteristics. For this purpose, they used previously generated and characterized transgenic mice engineered to express PrP devoid of glycans at the first, second or both N-glycosylation sites. The authors compared the infectious properties of prions passed on these transgenic mice with prion strains passaged in wild-type mice by in vivo strain typing and by the Standard Scrapie Cell Assay in vitro. The results show that the strain-specific characteristics of the 79A TSE strain changed when PrPSc was devoid of one or both glycans. The main conclusion of this study is that infectious properties of a TSE strain can be altered by glycosylation changes in PrP. The experiments are well done and use appropriate controls. The main problem with this paper is that I do not believe the new findings reported go sufficiently beyond the previosuly published study. In addition, the authors can still do not rule out the possibility that is the mutation rather than the changes on glycosylation that alter the strain properties. In this sense a more straightforward study by Supattapone's group (Piro et al., 2010) showed that changes in glycosylation of PrPSc do not alter strain properties. Surprisingly this article is not cited in the current manuscript. Referee #1:
1A. It would be helpful for the authors to more clearly explain how their data using glycosylation deficient PrPSc advances our understanding of strain switching over that of earlier studies using wild-type PrPSc.
Response:
-Two sentences in the discussion address this point o in paragraph 7 of the Discussion:
"This study is the first to demonstrate both in vivo and in vitro that post-translational modifications can significantly change the phenotypic characteristics of a TSE agent." o and in paragraph 12 of the Discussion:
"We have shown that glycosylation can be important in allowing selection of a mutant strains from 79A" -In addition, the following paragraph has been included at the end of the Discussion:
"In summary, the experiments reported here show that TSE infectivity can replicate in mice with glycosylation-deficient PrP (G1, G2 and G3), but with TSE strain-specific responses. Changes in the glycosylation status of PrP in the inoculum affected strain properties in some cases but not others, demonstrating that the carbohydrate moieties are not essential to TSE replication or retention of strain specific properties. Indeed despite the partial or complete absence of the carbohydrate moieties on PrP, TSE strain properties were maintained, or in the case of 79A altered to 139A in a similar fashion to changes taking place in wild type mice. In other cases strain properties changed and a new TSE agent phenotype emerged. Overall these results demonstrate that the glycosylation status of host PrP can affect the replication and selection of the fittest TSE strain in that environment but that TSE strain properties are independent from host PrP." -The final sentence particularly emphasises the point that referees highlighted.
1B. The authors need to more clearly define what they believe constitutes a mutation in a prion.
-The following sentence has been included to clarify the issue of mutation at the end of paragraph 1 of the discussion:
"Here we use the word "mutation" operationally without prejudging the underlying molecular mechanism by which information changes."
-In addition the first paragraph of the conclusion addresses hypothetical options for mutation to take place at the molecular level.
"Mutational change to TSE strains has long been recognised, probably occurring stochastically (Bruce and Dickinson, 1987; Kimberlin et al, 1987) . Recently it has been shown that TSE strains can mutate and be subject to selection in the presence of drugs (Ghaemmaghami et al, 2009; Li et al, 2010) or other alterations in the host environment, such as glycosylation status (Li et al, 2010; Mahal et al, 2010) . We have shown that glycosylation can be important in allowing selection of a mutant strains from 79A. According to the prion hypothesis, a population of TSE agent infectious units comprises many different PrPSc conformations, of which only one or a few form a majority in a particular host, constituting a quasi-species (Collinge, 2010; Li et al, 2010; Peretz et al, 2002; Weissmann et al, 2011) . However evidence for large numbers of conformations is not established nor is it clear whether all the required conformations would be sufficiently thermodynamically stable. Alternatively, heritable change, i.e. mutation, would require change, insertion or deletion of one or more nucleotides in a putative TSE nucleic acid genome (Somerville, 2002) , as is the case for any virus or other living organism with a nucleic acid based genome." Figure 7 , G1 needs to be changed to G2.
1/4. In the bottom set of panels in
-The figure has been altered. -We have added a sentence to the beginning of Results to summarise the passage histories.
2/3 P.9, nine lines from bottom: the sentence ending with "especially observed" needs fixing.
-"Especially observed" deleted.
2/4 P.10: It seems that "over 100 days" should be "~100 days" because by my calculation, one of the differences to which the authors refer was slightly less than 100 days.
-Agreed. "over " changed to "about"
2/5
The authors frequently make comparisons to the 139A strain without showing data or giving references to previously published data. One or the other should be provided.
-A reference to the properties of 139A has been added to their description at the first mention of 139A in Results.
2/6. P13, third line from bottom: G2 is mentioned, but the figure 7E is labelled G1. I assume the former is correct?
-The former is correct and the figure has been altered, (See referee 1/3) -See response 1A
The authors can still do not rule out the possibility that is the mutation rather than the changes on glycosylation that alter the strain properties. In this sense a more straightforward study by Supattapone's group (Piro et al., 2010) showed that changes in glycosylation of PrPSc do not alter strain properties. Surprisingly this article is not cited in the current manuscript. Response -We should have cited this article; we do so now in the Introduction and Discussion. This paper uses a very different approach. Native mouse PrPC was deglycosylated enzymatically and the PMCA reaction was used in this study. The deglycosylation approach is valid and complementary to the genetic approach. It has the advantage of avoiding the alteration of the amino acid sequence of PrP. However it is likely that a small undetectable proportion of PrP remained glycosylated and could have affected the outcome. Moreover, the PMCA reaction does not appear to replicate TSE infectivity in the same way as it is replicated in vivo. Clearly the conclusions of the two studies differ and the combined in vitro and in vivo approaches in this study add considerable strength to our conclusions.
